David Kaland

U.S. Food and Drug Administration Analysis of Newly Identified Adverse Events With Lurbinectedin: Extravasation, Rhabdomyolysis, and Tumor Lysis Syndrome

Case report · Clinical Lung Cancer · 2022 · First of 4 authors · Corresponding · 4 citations

Dasatinib-Associated Chylothorax: A Review of Cases Reported to the FDA Adverse Event Reporting System and the Published Literature

Letter or commentary · Lung · 2025 · First of 4 authors · Corresponding